Moses Huang

Randomized, double‐blind placebo‐ and tolterodine‐controlled trial of the once‐daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

Christopher R. Chapple, Tomasz Rechberger, P. J. MEFFAN et al. · British Journal of Urology · 2004 · 370 citations

RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF THE ONCE DAILY ANTIMUSCARINIC AGENT SOLIFENACIN SUCCINATE IN PATIENTS WITH OVERACTIVE BLADDER

L. Cardozo, M. LISEC, R. J. Millard et al. · The Journal of Urology · 2004 · 335 citations

Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)

Marcus J. Drake, Christopher R. Chapple, Adil Esen et al. · European Urology · 2016 · 181 citations · Full text

The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial

José E. Batista, H. Kölbl, Sender Herschorn et al. · Therapeutic Advances in Urology · 2015 · 83 citations · Full text

Pharmacokinetics and Safety of Solifenacin Succinate in Healthy Young Men

Ronald Smulders, Walter Krauwinkel, Pieter Swart et al. · The Journal of Clinical Pharmacology · 2004 · 65 citations

Adverse Events, Steady State, Pharmacological Study +8